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The aim of the present study was to assess the
efficacy and tolerability of a calcium antagonist/b-
blocker fixed combination tablet used as first-line
antihypertesnive therapy in comparison with an
angiotensin converting enzyme inhibitor and
placebo. Patients with uncomplicated essential
hypertension (diastolic blood pressure between 95
and 110 mm Hg at the end of a 4-week run-in
period) were randomly allocated to a double-blind,
12-week treatment with either a combination tablet
of felodipine and metoprolol (Logimax), 5/50 mg
daily (n 5 321), enalapril, 10 mg daily (n 5 321), or
placebo (n 5 304), with the possibility of doubling
the dose after 4 or 8 weeks of treatment if needed
(diastolic blood pressure remaining >90 mm Hg).
The combined felodipine–metoprolol treatment
controlled blood pressure (diastolic <90 mm Hg
24 h after dose) in 72% of patients after 12 weeks,
as compared with 49% for enalapril and 30% for
placebo. A dose adjustment was required in 38%
of patients receiving the combination, in 63% of
patients allocated to placebo, and 61% of enalapril-
treated patients. The overall incidence of adverse
events was 54.5% during felodipine–metoprolol
treatment; the corresponding values for enalapril
and placebo were 51.7% and 47.4%, respectively.
Withdrawal of treatment due to adverse events
occurred in 18 patients treated with the
combination, in 10 patients on enalapril, and 12
patients on placebo. No significant change in
patients’ well-being was observed in either of the
three study groups. These results show that a fixed
combination tablet of felodipine and metoprolol
allows to normalize blood pressure in a
substantially larger fraction of patients than
enalapril given alone. This improved efficacy is
obtained without impairing the tolerability. The
fixed-dose combination of felodipine and
metoprolol, therefore, may become a valuable
option to initiate antihypertensive treatment.
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Hypertension is a common disorder in in-dustrialized countries and is associatedwith an increased cardiovascular risk.1Antihypertensive therapy prevents to a
substantial degree the occurrence of complications
such as stroke and myocardial infarction.2 Therefore,
considerable efforts are directed worldwide to screen
for hypertensive patients and to treat them. The con-
trol of blood pressure at the community level remains,
however, a difficult task. This is obvious from the
rather small fraction of hypertensive patients who
have actually normalized their blood presssure by
antihypertensive therapy.3,4 For example, in a recent
survey carried out in the United States, less than half
of treated hypertensive patients achieved a blood
pressure that is generally considered as ideal (ie, a
systolic [SBP] and a diastolic blood pressure [DBP]
lower than 140 and 90 mm Hg, respectively, during
treatment).3
How could this suboptimal blood pressure control
be explained? One reason could be that the drugs
currently available are not effective enough, or are not
used in an optimal way. Occurrence of side effects that
reduces compliance is another important factor,5 and
in fact a lifelong compliance to treatment is difficult
for many patients is another reason.
Official guidelines recommend to initiate the phar-
macologic treatment of hypertension with medica-
tions given as monotherapies and, when needed, to
switch from one to another class of antihypertensive
agents (sequential monotherapy) or to associate two
medications lowering blood pressure by different
mechanisms (combination therapy).6,7 Recently, the
concept of low-, fixed-dose combination therapy has
gained increasing acceptance.8,9 This approach is
thought to maximize the antihypertensive efficacy and
to minimize the incidence of dose-dependent adverse
effects and has been proposed as a valuable choice for
starting antihypertensive therapy.
The present study addresses several critical issues
dealing with the practical management of hyperten-
sion. First, how does a first-line monotherapy-based
approach compare with a fixed-dose combination
treatment in terms of efficacy and tolerability? Second,
how do these two therapeutic options compare with
placebo, mainly in terms of tolerability? For this pur-
pose, patients with uncomplicated essential hyper-
tension were randomly allocated to a double-blind,
12-week treatment with either an angiotensin convert-
ing enzyme (ACE) inhibitor (enalapril), a fixed com-
bination tablet containing the dihydropyridine felo-
dipine extended-release formulation and the b-blocker
metoprolol controlled-release formulation (Logimax),
or placebo.
PATIENTS AND METHODS
Nine hundred forty-six patients with uncomplicated
essential hypertension were included in this multi-
center study. The number of randomized patients per
country were: UK, 125; Belgium, 118; Sweden, 110;
France, 106; Canada, 90; Norway, 82; Poland, 70;
Spain, 69; Greece, 56; Switzerland, 47; Finland, 40;
and Austria, 34. Patients were either untreated (n 5
494), or had their previous treatment withdrawn (n 5
452). They all had a mean sitting DBP between 95 and
110 mm Hg at the end of a 4-week placebo run-in
period. Before inclusion, all patients gave written in-
formed consent in accordance with the Helsinki dec-
laration. The study was approved by all local ethics
committees. All patients were considered able to un-
derstand and complete the general well-being ques-
tionnaire. Patients with a known intolerance to dihy-
dropyridine antagonists, b-blockers, or ACE inhibitors
were excluded.
The study was of parallel group design with a dou-
ble-blind, random allocation to a 12-week treatment
with either placebo (n 5 304), enalapril, 10 mg/day
(n 5 321), or a fixed combination tablet of felodipine
and metoprolol, 5/50 mg/day (n 5 321). The doses
were doubled after 4 or 8 weeks of treatment if mean
sitting DBP was not #90 mm Hg. The dose was also
doubled if, at any time after randomization, blood
pressure was .180/105 mm Hg. In this case, an extra
visit was scheduled within 7 days. The patient was
discontinued from the study if he or she still had, at
this extra visit, a blood pressure .180/105 mm Hg.
Sitting blood pressure, heart rate, and adverse
events were recorded at randomization, and at each
visit throughout the 12-week observation period.
Blood pressure was measured 24 h after the last intake
of the study medication. The measurements were al-
ways done in the same arm using a mercury sphyg-
momanometer and a cuff size appropriate to the pa-
tient’s arm; they were performed in duplicate, with
at least 1 min interval in between, to the nearest
2 mm Hg. The mean of the two readings was then
calculated. Heart rate was determined by pulse pal-
pation for 30 sec immediately after the blood pres-
sure measurement.
Statistical Evaluation The changes in blood pressure
and heart were analyzed by taking into account the
change from baseline to the end of the study. The
changes in the three treatment groups were compared
using a two-way analysis of variance model with
treatment and center as factors. Blood pressure and
heart rate were also analyzed after 4 weeks of treat-
ment. The proportion of patients with controlled
blood pressure (sitting DBP #90 mm Hg) were com-
pared between each one of the active treatment groups
and placebo using the Mantel-Haenszel test stratifying
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for center. Because of multiple comparisons a P value
less than .017 was considered significant for any pair-
wise comparison between treatments.
RESULTS
Table 1 shows the baseline demographic characteris-
tics of the patients. There were no apparent differences
in these parameters between the three groups.
Of the 946 randomized patients, 845 completed the
study. The remaining patients discontinued prema-
turely because of adverse events (n 5 40) or other
reasons (n 5 62), mainly because of blood pressure
above safety criteria (n 5 45). Among patients who
interrupted the treatment due to adverse events, 12
(3.9%) were taking placebo, 10 (3.1%) on enalapril, and
18 (5.6%) on the felodipine–metoprolol combination,
with no significant differences between groups. Two
to 4 weeks after the end of the study, three patients on
placebo had not yet recovered from the adverse effect
(glomerulonephritis, nightmares, and urticaria). The
corresponding numbers for the enalapril and the com-
bination therapy group were three (headache, cerebral
infarction, and retrosternal pain) and two (cholelithi-
asis and peripheral edema), respectively. During the
run-in phase the incidence of adverse events was
26.3%, 29.9%, and 29.3% in the placebo, enalapril, and
felodipine–metoprolol group, respectively. The corre-
sponding values for the new onset adverse events seen
during the randomized part of the trial were 42.4%,
45.8%, and 49.8%. Table 2 shows the new onset ad-
verse events that were observed in at least 10 patients
in any of the three study groups. As expected, the
most common adverse events were peripheral edema,
headache, and flushing in the felodipine–metoprolol
group. Most patients (12 of 18) who discontinued the
felodipine–metoprolol treatment did so because the
occurrence of at least one of these three adverse
events. This was also the case in 5 and 3 patients of the
12 and 10 patients who stopped prematurely placebo
or enalapril treatment, respectively.
In Figure 1 the changes in blood pressure (measured
24 h after dose) from baseline to the 12th week of
therapy are given. Both active treatments were signif-
icantly more effective in lowering blood pressure than
placebo. This was true for SBP (P , .001) as well as
DBP (P , 0.001). The reduction in blood pressure in
the felodipine–metoprolol group was significantly
greater than in the enalapril group (P , .001 for both
SBP and DBP). This significant difference was ob-
served after 4 and 12 weeks of treatment. Seventy-
three percent of patients in the placebo group and 61%
in the enalapril group required a dose increase com-
pared with only 38% in the felodipine–metoprolol
group.
The combined treatment controlled blood pressure
in 63% of patients after 4 weeks and 72% after 12
weeks. The corresponding values were 40% and 49%
for enalapril as compared with 30% and 40% for pla-
cebo. The proportion of patients with controlled DBP
FIGURE 1. Mean (6 1 SD) changes in seated blood pressure
(BP) after 4 and 12 weeks’ treatment, 24 h after dosing. Pl,
placebo; E, enalapril; FM, felodipine–metoprolol.
TABLE 1. CHARACTERISTICS OF THE PATIENTS








Male/female (n) 165/135 188/133 177/144
Age (years) 51.0 6 10.7 52.4 6 10.2 51.5 6 10.8
Weight (kg) 80.5 6 15.0 80.3 6 14.2 80.2 6 15.9
Height (cm) 168.3 6 9.8 168.8 6 9.4 168.9 6 9.9
Seated DBP
(mm Hg) 101.0 6 4.4 100.9 6 4.6 101.1 6 4.3
Seated SBP
(mm Hg) 157.2 6 15.3 158.0 6 15.4 157.6 6 15.3
Heart rate
(beats/min) 74.9 6 9.1 74.7 6 8.6 75.1 6 8.8
DBP, diastolic blood pressure; SBP, systolic blood pressure.
TABLE 2. MOST COMMON NEW ONSET ADVERSE
EVENTS (OCCURRING IN AT LEAST 10 PATIENTS









Headache 20 (6.6%) 16 (5.0%) 28 (8.7%)
Coughing 12 (3.9%) 23 (7.2%) 9 (2.8%)
Fatigue 10 (3.3%) 14 (4.4%) 18 (5.6%)
Edema 1 (0.3%) 3 (0.9%) 33 (10.3%)
Dizziness 9 (3%) 11 (3.4%) 15 (4.7%)
Flushing 11 (3.6%) 4 (1.2%) 17 (5.3%)
Respiratory infection 6 (2%) 16 (5%) 5 (1.6%)
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was significantly greater (P , .001) during felodipine–
metoprolol treatment than enalapril or placebo admin-
istration, both after 4 and 12 weeks. In this respect,
enalapril was also significantly better than placebo at
4 weeks (P , .01).
Heart rate was significantly decreased by the felo-
dipine–metoprolol combination by 3.1 6 8.5 beats/
min after 4 weeks and 5.6 6 9.4 beats/min after 12
weeks, whereas placebo and enalapril had no effect
(P , .001, felodipine–metoprolol versus placebo and
enalapril). No significant change in body weight was
observed during the course of the study.
DISCUSSION
One of the purposes of this large double-blind, place-
bo-controlled multicenter trial was to apply a new
approach of pharmacologic treatment of hypertension
(ie, the use of a low-dose combination as first-line
therapy). To this end a fixed-dose combination tablet
of the vasoselective dihydropyridine calcium antago-
nist felodipine (5 mg/day)10 and the cardioselective
b-blocker metoprolol (50 mg/day)11 was compared
with a medication lowering blood pressure by another
mechanism, the ACE inhibitor enalapril (10 mg/
day)12, and placebo. All drugs were administered once
daily. Enalapril was chosen as a reference single-agent
therapy because of its wide acceptance as a first-line
antihypertensive drug. The active treatments were sig-
nificantly more effective than placebo, with a clearcut
advantage for the felodipine–metoprolol combination
over the enalapril monotherapy. Overall adverse
events had the same incidence in patients receiving
placebo as in those allocated to enalapril or the felo-
dipine–metoprolol combination.
Combination therapy has advantages related to dif-
fering mechanisms of action of the individual drugs,
which include the potential to produce additive anti-
hypertensive effects. The association of a dihydropyr-
idine with a b-blocker is logical, especially because
blockade of cardiac b-adrenoceptor prevents the oc-
currence of any reflex heart rate acceleration induced
by the calcium antagonist-mediated peripheral vaso-
dilation. Actually, the felodipine–metoprolol combi-
nation is known to be more effective than the individ-
ual components given alone, while being as well
tolerated.13 The fixed-dose combination used in the
present study contains an extended-release formula-
tion of felodipine and a controlled-release formulation
of metoprolol. This preparation has been shown to
provide smooth drug plasma concentrations as well as
smooth blood pressure and heart rate effects over the
24-h dosing interval when administrered once a day.14
For example, the trough-to-peak ratio for this long-
acting felodipine–metoprolol combination is 84% for
SBP and 65% for DBP,15 which falls within the guide-
lines suggested by the US Food and Drug Adminis-
tration for administration of once-daily antihyperten-
sive drugs.16
The initial dosing of the active treatments was con-
ventional and could be doubled if needed after 4
weeks. It has to be pointed out that the dose increase
was required in clearly more patients randomized to
enalapril (61%) than in those receiving the drug com-
bination (38%). In this study, the dose adjustment
allowed to increase the fraction of patients with a DBP
#90 mm Hg by about 10%. The recommended dosing
of enalapril in essential hypertension is 10 to 20 mg
given once daily.17 It should be kept in mind in this
context that enalapril is rather short-acting. Therefore,
it is possible that a better blood pressure control
would have been achieved by increasing the dose of
enalapril to 20 mg twice a day.18
The lowering in blood pressure induced by the felo-
dipine–metoprolol combination, on the average of
18/14 mm Hg after 3 months of treatment, are prac-
tically identical to what has been previously observed
with the same preparation.13 The placebo arm was, as
anticipated, of crucial importance as blood pressure
was substantially lowered in the control group of pa-
tients, by a mean of 7/7 mm Hg at completion of the
trial (ie, to the same extent achieved by the ACE
inhibitor). Blood pressure was measured convention-
ally at the doctor’s office, like in all interventional
mega-trials performed so far. It should be empha-
sized, however, that the blood pressure readings were
always obtained at trough, 24 h after the last dosing.
This may lead to an underestimation of the blood
pressure response prevailing during most of the day.
Regarding the quality of blood pressure control, the
main message of the present study is that starting
therapy with a low-dose calcium antagonist/b-
blocker combination makes it possible to normalize
blood pressure in a greater number of patients than
with an ACE inhibitor as initial drug. Several other
studies have demonstrated the superiority of low-dose
combinations of antihypertensive agents over mono-
therapy with the individual components (even in
higher doses). This is, for example, the case for ACE
inhibitor/diuretic,19,20 ACE inhibitor/calcium antago-
nist,21,22 and b-blocker/diuretic23 combinations. It is
pertinent to note in this context that a low-dose com-
bination of the b1-adrenoceptor blocker bisoprolol
and hydrochlorothiazide23 has been approved by the
Food and Drug Administration in United States as a
first-line therapy.24 Furthermore, the low-dose re-
serpine–thiazide combination, which is generally
viewed as obsolete, is more effective in lowering blood
pressure than a modern calcium antagonist like ni-
trendipine given in monotherapy, while inducing
fewer side effects.25
Finally, the need for combining drugs acting by
different mechanisms to better control blood pressure
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is substantiated by the preliminary results of the Hy-
pertension Optimal Treatment study.26 In this morbid-
ity and mortality trial, patients were randomized to
three different target groups of either #90, #85, or
#80 mm Hg. The treatment was started in all patients
with felodipine, and a b-blocker or an ACE inhibitor
could then be added if the goal blood pressure was not
reached. At 6 months, 83% of the patients of the #90
mm Hg target group had achieved their target. The
corresponding figures for the #85 and #80 mm Hg
target group were 71% and 57%, respectively. Conse-
quently, more aggressive therapy was required for the
lower blood pressure targets, which is reflected by the
fact that combination therapy was used in 48%, 59%,
and 66% of the #90, #85, and #80 mm Hg target
groups, respectively.
When dealing with the pharmacologic treatment of
hypertension, a crucial issue is the tolerability of
drugs. Each antihypertensive agent might have basi-
cally two types of adverse effects: those that are or
those that are not dose dependent within the thera-
peutic dosing range.27 Combining low doses of drugs
with different modes of action on the cardiovascular
system minimizes the incidence of dose-dependent
side effects and could prevent the occurrence of some
adverse reactions triggered by the other constituent of
the combination.7–9 This pharmacologic rationale is to
some extent substantiated by the results of the present
study. Thus, there were no more clinical adverse ex-
periences in patients allocated to the combined treat-
ment than in those administered enalapril. In terms of
compliance, fixed-dose combinations also offer an ad-
vantage by enabling patients to follow a simple and
convenient therapeutic regimen.
Interestingly, the profile of adverse effects observed
from the felodipine–metoprolol treatment corre-
sponded to that expected during calcium entry block-
ade using a dihydropyridine (ie, edema, headache,
and flushing). These adverse effects are most likely
attributable to the felodipine-induced vasodilation. In
the present trial, they were by far the leading cause of
treatment discontinuation. Also interestingly, these
adverse effects have been shown previously to be less
frequent when felodipine is combined with metopro-
lol, as in this study, than when it is give alone.26
In conclusion, the present data show that the felo-
dipine–metoprolol combination tablet allows to nor-
malize blood pressure in a larger number of hyperten-
sive patients than enalapril used as a single agent.
They also show that this better antihypertensive effi-
cacy is not obtained at the expense of a decreased
tolerability. Low-dose fixed combinations, because of
their excellent efficacy, good tolerability, and simplic-
ity of use, are very useful to treat patients not ade-
quately controlled by monotherapy and therefore,
may become a valuable option to initiate antihyper-
tensive therapy.
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